HomeCompareAGTC vs EQR

AGTC vs EQR: Dividend Comparison 2026

AGTC yields 508.13% · EQR yields 4.73%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 AGTC wins by $69571.52M in total portfolio value
10 years
AGTC
AGTC
● Live price
508.13%
Share price
$0.39
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$69571.56M
Annual income
$50,154,845,926.92
Full AGTC calculator →
EQR
EQR
● Live price
4.73%
Share price
$58.58
Annual div
$2.77
5Y div CAGR
15.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$40.5K
Annual income
$3,819.61
Full EQR calculator →

Portfolio growth — AGTC vs EQR

📍 AGTC pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAGTCEQR
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, AGTC + EQR cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
AGTC pays
EQR pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

AGTC
Annual income on $10K today (after 15% tax)
$43,191.06/yr
After 10yr DRIP, annual income (after tax)
$42,631,619,037.88/yr
EQR
Annual income on $10K today (after 15% tax)
$401.93/yr
After 10yr DRIP, annual income (after tax)
$3,246.67/yr
At 15% tax rate, AGTC beats the other by $42,631,615,791.21/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of AGTC + EQR for your $10,000?

AGTC: 50%EQR: 50%
100% EQR50/50100% AGTC
Portfolio after 10yr
$34785.80M
Annual income
$25,077,424,873.26/yr
Blended yield
72.09%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EQR right now

AGTC
Analyst Ratings
9
Buy
5
Hold
Consensus: Buy
EQR
Analyst Ratings
16
Buy
28
Hold
2
Sell
Consensus: Hold
Price Target
$70.35
+20.1% upside vs current
Range: $63.00 — $78.50
Altman Z
1.8
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

AGTC buys
0
EQR buys
0
No recent congressional trades found for AGTC or EQR in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAGTCEQR
Forward yield508.13%4.73%
Annual dividend / share$2.00$2.77
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.8%
Portfolio after 10y$69571.56M$40.5K
Annual income after 10y$50,154,845,926.92$3,819.61
Total dividends collected$67890.24M$16.9K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyHold

Year-by-year: AGTC vs EQR ($10,000, DRIP)

YearAGTC PortfolioAGTC Income/yrEQR PortfolioEQR Income/yrGap
1← crossover$61,513$50,813.01$11,248$547.57+$50.3KAGTC
2$357,937$292,117.85$12,701$666.53+$345.2KAGTC
3$1,971,589$1,588,596.72$14,405$814.59+$1.96MAGTC
4$10,287,466$8,177,865.69$16,413$999.84+$10.27MAGTC
5$50,886,951$39,879,362.52$18,795$1,232.92+$50.87MAGTC
6$238,807,233$184,358,195.45$21,639$1,527.95+$238.79MAGTC
7$1,064,097,636$808,573,896.33$25,057$1,903.80+$1064.07MAGTC
8$4,505,792,438$3,367,207,967.63$29,197$2,385.87+$4505.76MAGTC
9$18,146,463,265$13,325,265,356.46$34,250$3,008.70+$18146.43MAGTC
10$69,571,561,621$50,154,845,926.92$40,467$3,819.61+$69571.52MAGTC

AGTC vs EQR: Complete Analysis 2026

AGTCStock

Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. Its advanced product candidates include three ophthalmology development programs across two targets, including X-linked retinitis pigmentosa, which is in the Phase 1/2 clinical trials; and achromatopsia that is in Phase 1/2 clinical trials. It is also developing an optogenetic product candidate to treat advanced retinal disease. In addition, the company has initiated one preclinical program in otology; preclinical program in dry age-related macular degeneration; and two preclinical programs in targeting central nervous system disorders, including frontotemporal dementia and amyotrophic lateral sclerosis. It has collaboration agreements with University of Florida; Bionic Sight, Inc.; and Otonomy, Inc. The company was incorporated in 1999 and is headquartered in Alachua, Florida.

Full AGTC Calculator →

EQRREIT

Equity Residential is committed to creating communities where people thrive. The Company, a member of the S&P 500, is focused on the acquisition, development and management of residential properties located in and around dynamic cities that attract high quality long-term renters. Equity Residential owns or has investments in 305 properties consisting of 78,568 apartment units, located in Boston, New York, Washington, D.C., Seattle, San Francisco, Southern California and Denver.

Full EQR Calculator →
📬

Get this AGTC vs EQR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

AGTC vs SCHDAGTC vs JEPIAGTC vs OAGTC vs KOAGTC vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.